Selection of a hepatitis B virus strain resistant to adefovir in a liver transplantation patient.

No abstract is available for this paper.

• Publication year

  2003

• Venue

  Journal of Hepatology

• Publication date

  2003-12-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1016/J.JHEP.2003.09.022PMID 14642631
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B.

  2003cited by this paper
• Resistance surveillance of HBEAG— chronic hepatitis B (CHB) patients treated for two years with adefovir dipivoxil (ADV)

  2003cited by this paper
• Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B.

  2003cited by this paper
• Histological outcome during long-term lamivudine therapy.

  2003cited by this paper
• Effects of Pyrimidine and Purine Analog Combinations in the Duck Hepatitis B Virus Infection Model

  2003cited by this paper
• Towards an improved and cost-saving prophylaxis of hepatitis B virus recurrence after liver transplantation?

  2003cited by this paper
• Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B.

  2003cited by this paper
• Adefovir dipivoxil (ADV) alone and in combination with lamivudine (LAM) suppresses LAM-resistant hepatitis B virus (HBV) replication: 16 week interim analysis

  2002cited by this paper
• A Preliminary Benefit-Risk Assessment of Lamivudine for the Treatment of Chronic Hepatitis B Virus Infection

  2002cited by this paper
• Adefovir dipivoxil (ADV) for the treatment of lamivudine resistant HBV (LAM-R) in post liver transplant (post-OLT) patients

  2002cited by this paper
• Resistance surveillance in chronic hepatitis B patients treated with adefovir dipivoxil for up to 60 weeks

  2002cited by this paper
• Inhibitory activity of dioxolane purine analogs on wild‐type and lamivudine‐resistant mutants of hepadnaviruses

  2002cited by this paper
• Molecular Modeling and Biochemical Characterization Reveal the Mechanism of Hepatitis B Virus Polymerase Resistance to Lamivudine (3TC) and Emtricitabine (FTC)

  2001cited by this paper
• Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study.

  2001cited by this paper
• Extended lamivudine treatment in patients with chronic hepatitis B enhances hepatitis B e antigen seroconversion rates: Results after 3 years of therapy

  2001cited by this paper
• Duck hepatitis B virus polymerase gene mutants associated with resistance to lamivudine have a decreased replication capacity in vitro and in vivo.

  2001cited by this paper
• Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  2000cited by this paper
• In Vitro Antihepadnaviral Activities of Combinations of Penciclovir, Lamivudine, and Adefovir

  2000cited by this paper
• Adefovir dipivoxil for the treatment of lamivudine‐resistant hepatitis B mutants

  2000cited by this paper
• Evolution of hepatitis B virus polymerase gene sequence during famciclovir therapy for chronic hepatitis B.

  2000cited by this paper
• Early detection of viral resistance by determination of hepatitis B virus polymerase mutations in patients treated by lamivudine for chronic hepatitis B

  2000cited by this paper
• Multicenter study of lamivudine therapy for hepatitis B after liver transplantation

  1999cited by this paper
• Fulminant hepatic failure resulting from lamivudine-resistant hepatitis B virus in a renal transplant recipient: durable response after orthotopic liver transplantation on adefovir dipivoxil and hepatitis B immune globulin.

  1999cited by this paper
• Lamivudine as initial treatment for chronic hepatitis B in the United States.

  1999cited by this paper
• A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group.

  1998cited by this paper
• Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group.

  1998cited by this paper
• Identification and characterization of mutations in hepatitis B virus resistant to lamivudine

  1998cited by this paper
• Hepatitis-B-virus resistance to lamivudine given for recurrent infection after orthotopic liver transplantation.

  1997cited by this paper
• Synergistic inhibition of hepadnaviral replication by lamivudine in combination with penciclovir in vitro

  1997cited by this paper
• Mutation in HBV RNA‐dependent DNA polymerase confers resistance to lamivudine in vivo

  1996cited by this paper
• Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine

  1996cited by this paper
• A novel method for efficient amplification of whole hepatitis B virus genomes permits rapid functional analysis and reveals deletion mutants in immunosuppressed patients

  1995cited by this paper
• Mutations affecting hepadnavirus plus-strand DNA synthesis dissociate primer cleavage from translocation and reveal the origin of linear viral DNA

  1991cited by this paper

• Performance evaluation of a fully automated deep sequencing platform for hepatitis B genotyping and resistance testing.

  2025cites this paper
• Prevalence, clinical and virological characteristics and short‐term prognosis of hepatitis delta infection among patients with HIV/HBV in Nouakchott, Mauritania

  2024cites this paper
• Synthesis, Anticancer and Antiviral Activity Studies of 1,3,4-Oxadiazoles: A Review

  2022cites this paper
• Analysis of hepatic fibrosis markers in the serum of chronic hepatitis B patients according to basal core promoter/precore mutants

  2022cites this paper
• A morphometric analysis of hepatitis B subviral particles shows no correlation of filament proportion and length with clinical stage and genotype

  2022cites this paper
• Residual risk of mother-to-child transmission of hepatitis B virus infection despite timely birth-dose vaccination in Cameroon (ANRS 12303): a single-centre, longitudinal observational study.

  2022cites this paper
• Evolution and phenotypic characterization of whole HBV genome in compliant patients experiencing unexplained entecavir treatment failure.

  2021cites this paper
• Revisiting HBV resistance to entecavir with a phenotypic approach.

  2020cites this paper
• Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?

  2020cites this paper
• Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)-Infektion

  2020cites this paper
• Evaluation of the Aptima™ HBV Quant Dx assay for semi-quantitative HBV viral load from dried blood spots.

  2020cites this paper
• Pharmacokinetics and Pharmacodynamics of Antiviral Drugs in Special Population

  2019cites this paper
• Clinical Manifestations and Laboratory Tests of AECHB and Severe Hepatitis (Liver Failure)

  2019cites this paper
• Acute Exacerbation of Chronic Hepatitis B: Volume 2. Diagnosis and Management

  2019cites this paper
• KASL clinical practice guidelines for management of chronic hepatitis B

  2019cites this paper
• Deep sequencing of hepatitis B surface antigen gene in the preserved umbilical cords in immunoprophylaxis failure against mother-to-child HBV transmission

  2019cites this paper
• Determination of Pharmacokinetics and Pharmacodynamics of Lamivudine After Highdoses in Duck Hepatitis B Virus-Infected Pekin Ducks

  2018cites this paper
• Occult Hepatitis B Virus Infection: An Old Entity With Novel Clinical Involvements

  2018cites this paper
• Antiviral therapy of chronic hepatitis

  2017cites this paper
• Management of Antiviral Resistance in Chronic Hepatitis B

  2017influential citation
• Genotypic Assays for Monitoring Drug Resistance in HIV-1 Infection and for Other Chronic Viral Diseases

  2017cites this paper
• Emerging drugs for hepatitis

  2017cites this paper
• A novel method for nucleos(t)ide analogues susceptibility assay of hepatitis B virus by viral polymerase transcomplementation.

  2016cites this paper
• Development and validation of an oligonucleotide ligation assay to detect lamivudine resistance in hepatitis B virus.

  2016cites this paper
• Profile of HBV polymerase gene mutations during entecavir treatment in patients with chronic hepatitis B.

  2016cites this paper
• Different precore/core mutations of hepatitis B interact with, limit, or favor liver fibrosis severity

  2016cites this paper
• Lamivudine-resistant rtL180M and rtM204I/V are persistently dominant during combination rescue therapy with entecavir and adefovir for hepatitis B

  2016cites this paper
• KASL clinical practice guidelines: management of chronic hepatitis B

  2016cites this paper
• Safety and efficacy of entecavir in adefovir‐experienced patients

  2015cites this paper
• Delayed Reduction of Hepatitis B Viral Load and Dynamics of Adefovir-Resistant Variants during Adefovir plus Entecavir Combination Rescue Therapy

  2015cites this paper
• Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial

  2015cites this paper
• Inhibitory effect of Phyllanthus urinaria L. extract on the replication of lamivudine-resistant hepatitis B virus in vitro

  2015cites this paper
• Evolution of entecavir-resistant hepatitis B virus during entecavir and adefovir dipivoxil combination therapy

  2015cites this paper
• Effect of the HBV Capsid Assembly Inhibitor Bayer 41-4109 on the Intracellular Localization of EGFP-Core Fusion Proteins

  2015cites this paper
• Adefovir dipivoxil for adults with lamivudine‐resistant chronic hepatitis B virus infection

  2015cites this paper
• Entecavir plus adefovir combination therapy versus lamivudine add‐on adefovir for lamivudine‐resistant chronic hepatitis B: A meta‐analysis

  2014cites this paper
• Persistent viremia in human immunodeficiency virus/hepatitis B coinfected patients undergoing long‐term tenofovir: Virological and clinical implications

  2014cites this paper
• Mechanisms of Hepatitis B Virus Resistance Development

  2014cites this paper
• Strategies for the prevention of recurrent hepatitis B virus infection after liver transplantation.

  2014cites this paper
• Virologie de l’hépatite B

  2014cites this paper
• HBV Therapy and the Problem of Drug Resistance

  2014cites this paper
• Molecular diagnosis and treatment of drug-resistant hepatitis B virus.

  2014cites this paper
• Hepatitis B e antigen‐suppressing mutations enhance the replication efficiency of adefovir‐resistant hepatitis B virus strains

  2013cites this paper
• Prevalence, risk factors, and impact of isolated antibody to hepatitis B core antigen and occult hepatitis B virus infection in HIV-1-infected pregnant women.

  2013cites this paper
• Optimization of in vitro HBV replication and HBsAg production in HuH7 cell line.

  2013cites this paper
• High Endemicity and Low Molecular Diversity of Hepatitis B Virus Infections in Pregnant Women in a Rural District of North Cameroon

  2013cites this paper
• Efficacy and safety of telbivudine plus adefovir dipivoxil combination therapy and entecavir monotherapy for HBeAg‐positive chronic hepatitis B patients with resistance to adefovir dipivoxil

  2013cites this paper
• Prognosis of 153 patients with decompensated hepatitis B virus-related cirrhosis is improved after 3-year continuous lamivudine treatment.

  2013cites this paper
• Comprehensive analysis of Hepatitis B virus antiviral drug resistance mutations based on a new high-throughput phenotypic assay

  2013cites this paper
• Dynamics of lamivudine-resistant hepatitis B virus strains in patients with entecavir rescue therapy

  2013cites this paper
• Treatment of HBeAg positive chronic hepatitis B: interferon or nucleoside analogues

  2013cites this paper
• Optimal management of chronic hepatitis B patients with treatment failure and antiviral drug resistance

  2013influential citation
• Epidemiological, virological and clinical characteristics of HBV infection in 223 HIV co-infected patients: a French multi-centre collaborative study

  2013cites this paper
• Safe Blood Transfusion : Screening for Hepatitis B and Hepatitis C Virus Infections in Potential Blood Donors in Rural Southeast Asia LE VIET

  2013cites this paper
• Performance evaluation of the HepB Typer-Entecavir kit for detection of entecavir resistance mutations in chronic hepatitis B

  2013cites this paper
• Impact of rtI233V mutation in hepatitis B virus polymerase protein and adefovir efficacy: Homology modeling and molecular docking studies

  2013cites this paper
• Analysis of residual perinatal transmission of hepatitis B virus (HBV) and of genetic variants in human immunodeficiency virus and HBV co-infected women and their offspring.

  2013cites this paper
• Dynamics of hepatitis B virus resistance substitutions correlates with virological response in lamivudine-refractory patients with entecavir rescue monotherapy.

  2013cites this paper
• Performance of rapid tests for detection of HBsAg and anti-HBsAb in a large cohort, France.

  2013cites this paper
• Efficacy of Adefovir-based Combination Therapy for Patients with 1 Lamivudine-and Entecavir-Resistant Chronic Hepatitis B 2 3 Rescue therapy in LAM-and ETV-resistant CHB patients

  2013cites this paper
• Efficacy of Adefovir-Based Combination Therapy for Patients with Lamivudine- and Entecavir-Resistant Chronic Hepatitis B Virus Infection

  2013influential citation
• KASL Clinical Practice Guidelines: Management of chronic hepatitis B

  2012cites this paper
• Management of Recurrent HCV and HBV Infections after Liver Transplantation

  2012cites this paper
• Immunoprophylaxis against and prevention of recurrent viral hepatitis after liver transplantation

  2012cites this paper
• Antiviral efficacy of combination therapy with entecavir and adefovir for entecavir/lamivudine‐resistant hepatitis B virus with or without adefovir resistance

  2012influential citation
• Phenotypic assay of a hepatitis B virus strain carrying an rtS246T variant using a new strategy

  2012cites this paper
• Antiviral therapy of decompensated hepatitis B virus-related cirrhosis.

  2012cites this paper
• rtL180M mutation of hepatitis B virus is closely associated with frequent virological resistance to adefovir dipivoxil therapy

  2012cites this paper
• 11 Management of Recurrent HCV and HBV Infections after Liver Transplantation

  2012influential citation
• Long-Term Hepatitis B Virus (HBV) Response to Lamivudine-Containing Highly Active Antiretroviral Therapy in HIV-HBV Co-Infected Patients in Thailand

  2012cites this paper
• Antiviral therapies: focus on hepatitis B reverse transcriptase.

  2012influential citation
• Clonal evolution of hepatitis B virus polymerase gene mutations during lamivudine-adefovir combination treatment.

  2012cites this paper
• Characterization of Hepatitis B Viral Drug Resistance inIndian Subcontinent Patients with Chronic Liver Disease.

  2012cites this paper
• Management of treatment failure in chronic hepatitis B.

  2012influential citation
• Evolutionary pattern of full hepatitis B virus genome during sequential nucleos(t)ide analog therapy.

  2011cites this paper
• Four‐year study of lamivudine and adefovir combination therapy in lamivudine‐resistant hepatitis B patients: influence of hepatitis B virus genotype and resistance mutation pattern

  2011cites this paper
• The efficacy of entecavir therapy in chronic hepatitis B patients with suboptimal response to adevofir

  2011cites this paper
• Hepatitis B and D

  2011cites this paper
• Entecavir treatment for chronic hepatitis B: Adaptation is not needed for the majority of naïve patients with a partial virological response

  2011cites this paper
• Hepatitis B virus infection: pathogenesis, reactivation and management in hematopoietic stem cell transplant recipients

  2011cites this paper
• De novo combination therapy with lamivudine and adefovir dipivoxil in chronic hepatitis B patients.

  2011cites this paper
• Characterization of hepatitis virus B isolated from a multi-drug refractory patient.

  2011cites this paper
• Current Nucleos(t)ide Analogue Therapy for Chronic Hepatitis B

  2011cites this paper
• Virological response to adefovir monotherapy and the risk of adefovir resistance.

  2011cites this paper
• Hepatitis B virus drug resistance to current nucleos(t)ide analogs: Mechanisms and mutation sites

  2011cites this paper
• Antiviral activity of various 1-(2'-deoxy-β-D-lyxofuranosyl), 1-(2'-fluoro-β-D-xylofuranosyl), 1-(3'-fluoro-β-D-arabinofuranosyl), and 2'-fluoro-2',3'-didehydro-2',3'-dideoxyribose pyrimidine nucleoside analogues against duck hepatitis B virus (DHBV) and human hepatitis B virus (HBV) replication.

  2010cites this paper
• Antiviral Therapy for Hepatitis B in Pre- and Post-liver Transplant Patients

  2010cites this paper
• Antiviral drug resistance: mechanisms and clinical implications.

  2010cites this paper
• Low efficacy of entecavir therapy in adefovir‐refractory hepatitis B patients with prior lamivudine resistance

  2010cites this paper
• New pharmacologic therapies in chronic hepatitis B.

  2010cites this paper
• Drug Delivery Systems and Liver Targeting for the Improved Pharmacotherapy of the Hepatitis B Virus (HBV) Infection

  2010cites this paper
• Fitness and infectivity of drug-resistant and cross-resistant hepatitis B virus mutants: why and how is it studied?

  2010cites this paper
• Antiviral drug resistance: mechanisms and clinical implications.

  2010cites this paper
• rtE218G, a novel hepatitis B virus mutation with resistance to adefovir dipivoxil in patients with chronic hepatitis B

  2010cites this paper
• Virologic response at 12 months of treatment predicts sustained antiviral efficacy in patients with adefovir-treated Lamivudine-resistant chronic hepatitis B.

  2010cites this paper
• Antiviral Treatment of Chronic Hepatitis B Virus (HBV) Infections

  2010cites this paper
• Lamivudine plus adefovir or entecavir for patients with chronic hepatitis B resistant to lamivudine and adefovir.

  2010cites this paper
• Infectivity and vaccination efficacy studies in animal models of HBV S and pol gene mutants.

  2010cites this paper
• Antiviral effect of entecavir in chronic hepatitis B: influence of prior exposure to nucleos(t)ide analogues.

  2010cites this paper
• A Review of Hepatitis B Management in Pre- and Post-Liver Transplant Recipients

  2010cites this paper